Claims for Patent: 12,295,953
✉ Email this page to a colleague
Summary for Patent: 12,295,953
| Title: | Oral gliptin compositions and method for preparation thereof |
| Abstract: | Described herein are liquid oral gliptin compositions. The liquid oral gliptin compositions may comprise a gliptin or a pharmaceutically acceptable salt thereof, an artificial non-sugar alcohol sweetening agent, and liquid oral gliptin compositions may have a sugar alcohol content of less 25 w/v %. The liquid oral gliptin compositions described herein have improved taste and stability. Further provided herein are methods of manufacturing liquid oral gliptin compositions. |
| Inventor(s): | Ioannis Psarrakis, Konstantinos Lioumis |
| Assignee: | Pharma Data Research And Development Single Member SA |
| Application Number: | US18/587,175 |
| Patent Claims: |
1. An aqueous liquid oral gliptin composition comprising: about 2.5-about 3.5 w/v % of sitagliptin or a pharmaceutically acceptable salt or ester thereof; a thickening agent, wherein the thickening agent is selected from the group consisting of hydroxyethylcellulose, hydroxypropylcellulose, sodium alginate, sodium carboxymethylcellulose, gellan gum, polyethylene oxide polymer, and any combination thereof, wherein the thickening agent is present in the aqueous liquid oral gliptin composition at about 0.1-about 2.0 w/v %; an artificial non-sugar alcohol sweetening agent, wherein the artificial non-sugar alcohol sweetening agent is selected from the group consisting of sucralose, sodium saccharin, aspartame, acesulfame-K, cyclamate, and any combination thereof, wherein the artificial non- sugar alcohol sweetening agent is present in the aqueous liquid oral gliptin composition at 1-5 w/v %; wherein the aqueous liquid oral gliptin composition has a sugar alcohol content of less than 20 w/v %; an antioxidant; a buffering agent; and a preservative; and wherein the pH of the aqueous liquid oral gliptin composition is from 3 to 8. 2. The aqueous liquid oral gliptin composition of claim 1, wherein the sitagliptin is in the form of a chloride or a phosphate salt. 3. The aqueous liquid oral gliptin composition of claim 1, wherein the thickening agent is selected from the group consisting of hydroxyethylcellulose, hydroxypropylcellulose, sodium carboxymethylcellulose, and any combination thereof. 4. The aqueous liquid oral gliptin composition of claim 1, wherein the thickening agent is present in the aqueous liquid oral gliptin composition at about 0.1-about 0.8 w/v %. 5. The aqueous liquid oral gliptin composition of claim 1, wherein the thickening agent is present in the aqueous liquid oral gliptin composition at about 0.4-about 0.6 w/v %. 6. The aqueous liquid oral gliptin composition of claim 1, wherein the artificial non-sugar alcohol sweetening agent is a combination of sucralose and sodium saccharin, or a combination of sucralose and acesulfame-K. 7. The aqueous liquid oral gliptin composition of claim 6, wherein the sucralose is present in the aqueous liquid oral gliptin composition at about 0.8-about 2.0 w/v %. 8. The aqueous liquid oral gliptin composition of claim 6, wherein the acesulfame-K is present in the aqueous liquid oral gliptin composition at about 0.2-about 1.0 w/v %. 9. The aqueous liquid oral gliptin composition of claim 1, wherein the antioxidant is selected from the group consisting of butylated hydroxyl anisole, sodium metabisulfite, butylated hydroxyl toluene, and any combination thereof, and wherein the antioxidant is present in the aqueous liquid oral gliptin composition at about 0.01-about 0.10 w/v %. 10. The aqueous liquid oral gliptin composition of claim 1, wherein the buffering agent comprises a citrate. 11. The aqueous liquid oral gliptin composition of claim 1, wherein the buffering agent is present in the aqueous liquid oral gliptin composition at about 0.1-about 1.0 w/v %. 12. The aqueous liquid oral gliptin composition of claim 1, wherein the pH of the aqueous liquid oral gliptin composition is from 4 to 7. 13. The aqueous liquid oral gliptin composition of claim 1, wherein the preservative is selected from the group consisting of methyl paraben, ethyl paraben, propyl paraben, butyl paraben, any combination thereof, and any salt thereof. 14. The aqueous liquid oral gliptin composition of claim 1, wherein the preservative is present in the aqueous liquid oral gliptin composition at about 0.1-about 0.5 w/v %. 15. The aqueous liquid oral gliptin composition of claim 1, further comprising a chelating agent, and wherein the chelating agent is selected from the group consisting of disodium edentate salt, tartaric acid, malic acid, citric acid, and any combination thereof. 16. The aqueous liquid oral gliptin composition of claim 1, further comprising a wetting agent, and wherein the wetting agent is selected from the group consisting of sorbitan esters of fatty acids, sorbitan monolaurate, sorbitan monooleate, sorbitan trioleate, fatty alcohol-polyethylene glycol ethers, polysorbate 80, and any combination thereof. 17. The aqueous liquid oral gliptin composition of claim 1, further comprising a flavouring agent. 18. The aqueous liquid oral gliptin composition of claim 17, wherein the flavouring agent is selected from the group consisting of forest fruits flavour, strawberry, raspberry, cherry, cranberry, blueberry, black currant, red currant, gooseberry, lingonberries, and any combination thereof. 19. The aqueous liquid oral gliptin composition of claim 1, wherein the aqueous liquid oral gliptin composition has a sugar alcohol content of less than 10 w/v %. 20. The aqueous liquid oral gliptin composition of claim 19, wherein the aqueous liquid oral gliptin composition has a sugar alcohol content of less than 5 w/v %. 21. The aqueous liquid oral gliptin composition of claim 1, wherein the aqueous liquid oral gliptin composition comprises at less than 1% total impurities after storage of 9 months at 25° C. and 60% humidity. 22. The aqueous liquid oral gliptin composition of claim 1, wherein the aqueous liquid oral gliptin composition comprises at least 95% of the gliptin or a pharmaceutically acceptable salt or ester thereof after storage of 18 months at 25° C. and 60% humidity. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
